汇宇制药-W
(688553)
| 流通市值：52.11亿 | | | 总市值：64.28亿 |
| 流通股本：5.07亿 | | | 总股本：6.26亿 |
| 利润表 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 营业总收入 | 269,206,581.35 | 998,144,952.02 | 741,750,405.84 | 453,118,838.7 |
| 营业总成本 | 241,878,348.21 | 923,789,392.55 | 685,551,126.24 | 429,857,375.39 |
| 其他经营收益 | | | | |
| 营业利润 | 15,990,634.05 | -66,224,823.77 | -77,308,939.17 | -106,348,071.78 |
| 利润总额 | 16,509,516.45 | -64,312,837.41 | -76,284,509.37 | -105,004,897.27 |
| 净利润 | 21,719,987.14 | -30,547,754.14 | -55,069,850.69 | -83,595,454.15 |
| 每股收益 | | | | |
| 其他综合收益 | 622,982.18 | -1,957,391.72 | -2,111,898.33 | -2,483,729.31 |
| 综合收益总额 | 22,342,969.32 | -32,505,145.86 | -57,181,749.02 | -86,079,183.46 |
| 资产负债表 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 流动资产: | | | | |
| 流动资产合计 | 3,300,019,544.8 | 3,172,647,770.55 | 3,076,352,843.48 | 3,050,315,231.23 |
| 非流动资产: | | | | |
| 非流动资产合计 | 1,828,552,778.27 | 1,846,851,657.39 | 1,799,884,807.16 | 1,785,408,717.56 |
| 资产总计 | 5,128,572,323.07 | 5,019,499,427.94 | 4,876,237,650.64 | 4,835,723,948.79 |
| 流动负债: | | | | |
| 流动负债合计 | 1,264,771,219.65 | 1,180,890,006.01 | 1,078,930,576.55 | 1,065,523,023.71 |
| 非流动负债: | | | | |
| 非流动负债合计 | 94,512,328.12 | 91,663,615.95 | 76,328,749.84 | 78,120,035.27 |
| 负债合计 | 1,359,283,547.77 | 1,272,553,621.96 | 1,155,259,326.39 | 1,143,643,058.98 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 3,780,688,229.17 | 3,758,196,107.46 | 3,730,907,553.04 | 3,700,619,880.25 |
| 股东权益合计 | 3,769,288,775.3 | 3,746,945,805.98 | 3,720,978,324.25 | 3,692,080,889.81 |
| 负债和股东权益合计 | 5,128,572,323.07 | 5,019,499,427.94 | 4,876,237,650.64 | 4,835,723,948.79 |
| 现金流量表 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 318,245,959.91 | 1,288,217,879.42 | 1,031,888,173.09 | 662,102,482.55 |
| 经营活动现金流出小计 | 298,079,378.8 | 1,197,704,433.28 | 1,000,719,839.81 | 689,168,198.86 |
| 经营活动产生的现金流量净额 | 20,166,581.1 | 90,513,446.14 | 31,168,333.28 | -27,065,716.31 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 78,304,634 | 687,482,786.28 | 583,495,601.6 | 265,723,545.94 |
| 投资活动现金流出小计 | 123,457,865.81 | 556,693,826.78 | 445,355,562.18 | 284,722,115.35 |
| 投资活动产生的现金流量净额 | -45,153,231.81 | 130,788,959.5 | 138,140,039.42 | -18,998,569.41 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 331,900,000 | 901,146,000 | 625,071,444.45 | 594,071,444.45 |
| 筹资活动现金流出小计 | 247,171,723.58 | 801,197,069.61 | 725,591,146.71 | 683,797,288.37 |
| 筹资活动产生的现金流量净额 | 84,728,276.42 | 99,948,930.39 | -100,519,702.26 | -89,725,843.92 |
| 汇率变动对现金及现金等价物的影响 | -1,818,039.13 | -726,383.54 | 3,909,781.69 | 3,959,643.3 |
| 现金及现金等价物净增加额 | 57,923,586.58 | 320,524,952.49 | 72,698,452.13 | -131,830,486.35 |
| 期末现金及现金等价物余额 | 2,435,692,785.59 | 2,377,769,199.01 | 2,129,942,698.64 | 1,925,413,760.17 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | 320,524,952.49 | - | -131,830,486.35 |